Semaglutide
(Ozempic, Wegovy, Rybelsus) in Grand Junction, CO
Physicians near Grand Junction, CO from the federal NPI registry. Ask each office whether it prescribes Ozempic, Wegovy, or Rybelsus.[9]
- Ozempic: FDA-approved for type 2 diabetes.
- Wegovy: FDA-approved for chronic weight management.
- Rybelsus: FDA-approved for type 2 diabetes.
Same molecule (semaglutide): Ozempic in Grand Junction, Wegovy in Grand Junction
Other GLP-1 medicines: Tirzepatide in Grand Junction, Mounjaro in Grand Junction, Zepbound in Grand Junction
Find a physician in Grand Junction.
Every entry comes from the federal NPI registry. Ask each office what it prescribes. We do not accept payment for placement.
How to get Semaglutide in Grand Junction.
26 GLP-1 prescribers and 7 local resource types are on record for Grand Junction, plus 3 nearby towns in the directory.
Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Colorado’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.
The molecule in Ozempic, Rybelsus, and Wegovy. The brands differ in approved use and maximum dose.
Semaglutide is a once-weekly GLP-1 receptor agonist sold under three brand names by Novo Nordisk: Ozempic and Rybelsus for type 2 diabetes, and Wegovy for chronic weight management. It mimics a gut hormone that signals satiety to the brain and slows gastric emptying. The injectable forms share the same molecule; only the approved indication and maximum dose differ.[2][3]
In the STEP-1 obesity trial, adults without diabetes taking Wegovy (semaglutide 2.4 mg) lost a mean of 14.9% of body weight at 68 weeks versus 2.4% with placebo. In the SELECT trial, semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease but without diabetes.[1]
Community health · CDC
Weight & metabolic health in Grand Junction
Grand Junction, Colorado has a population of 65,560 people. The adult obesity rate in Grand Junction is an age-adjusted estimate of 30.6%, 5.6 percentage points above the Colorado state rate of 25%. Diagnosed diabetes reaches 8.3% of adults in Grand Junction. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 19.3% of adults in Grand Junction.
- of Grand Junction adults have obesity
- 30.6%
- diagnosed diabetes
- 8.3%
- no regular physical activity
- 19.3%
Age-adjusted estimates for Grand Junction, community figures, not individual risk. CDC PLACES, 2025 release.
The prescription is one part. Here is the rest, in Grand Junction.
Trials of semaglutide paired the drug with diet counseling and regular activity. Every name below is a real listing near Grand Junction, CO, ordered as the registry lists them, never by who pays us.
Nutritionists
A nutritionist helps you get enough protein and fiber while the medication cuts your appetite. Call to ask what they cover.
Gyms near you
A gym gives you the regular movement that keeps muscle while the weight comes off.
What the trials actually showed.
We summarize the STEP weight-management program, the SUSTAIN diabetes program, and the SELECT cardiovascular outcomes trial. Figures are means at each trial's primary endpoint.
Most Semaglutide side effects are stomach and gut effects.
In Wegovy's weight trials at 2.4 mg, the most common side effects were nausea (44%), diarrhea (30%), vomiting (24%), and constipation (24%). Ozempic's lower diabetes doses showed lower rates.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[1]
What Semaglutide costs, by how you pay.
The price you pay depends on your insurance plan, your diagnosis, and how you buy. Manufacturer self-pay programs cost far less than pharmacy retail. Here are the ranges.
Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk self-pay and savings pages.
Self-pay and savings card prices checked . Retail averages from May 2026.
| Wegovy, pharmacy retail | $1,610 to $1,788 | per month | Brand-name retail average, May 2026[6] |
|---|---|---|---|
| Wegovy, NovoCare self-pay | $349 to $399 | per month | Pen $349, Wegovy HD 7.2 mg $399. Pill $149 to $299 |
| Ozempic, pharmacy retail | $1,476 | per month | Brand-name retail average, May 2026[6] |
| Commercial insurance (T2D) | $25 to $250 | per month copay | Usually covered for diabetes with prior authorization |
| Commercial insurance (weight) | Often denied | Wegovy is on-label but frequently requires PA and is denied | |
| Medicare Part D | $0 to $100 | per month | Type 2 diabetes covered. Wegovy for weight management is $50 a month through the Medicare GLP-1 Bridge, Jul 2026 to Dec 2027[5] |
| Manufacturer savings card | as low as $25 | per month | Ozempic and Wegovy cards, commercial insurance only, up to $100 a month in savings |
Physicians from the federal NPI registry. Ask each office whether it prescribes Semaglutide.
Physicians from the federal NPI registry in the states we cover. Ask each office whether it prescribes Semaglutide.
The questions people ask before they book.
Answers reviewed by the glp·helper Medical Team. Citations link to primary sources, never marketing copy.
Semaglutide is the active ingredient in three Novo Nordisk brands: Ozempic, Wegovy, and Rybelsus. No generic semaglutide is FDA-approved in the US. Ozempic and Rybelsus are approved for type 2 diabetes; Wegovy is approved for chronic weight management at a higher maximum dose (7.2 mg/week, Wegovy HD). Insurers treat the brands as separate drugs.[1]
Yes. Semaglutide is a prescription-only medicine. The Ozempic and Wegovy labels both say Rx only. A licensed prescriber (MD, DO, NP, or PA) must evaluate you before issuing a prescription.[1]
In most states, yes. Telehealth prescribing is permitted once a practitioner-patient relationship is established, typically via a synchronous video visit, by a provider licensed in your state.[1]
In the STEP-1 trial, adults without diabetes lost a mean of 14.9% of body weight over 68 weeks on Wegovy 2.4 mg, versus 2.4% on placebo. Individual results vary with dose, adherence, diet, and activity.[2]
Glucose effects appear within 1 to 2 weeks. Weight effects accrue over several months as the dose is escalated; most patients reach maintenance dosing after 8 to 16 weeks of titration.[1]